Silence Therapeutics (NASDAQ:SLN) Announces Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Silence Therapeutics (NASDAQ:SLN) posted its quarterly earnings results on Thursday. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.13), FiscalAI reports. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%.

Silence Therapeutics Stock Up 0.2%

Shares of NASDAQ SLN opened at $19.80 on Friday. The business’s 50 day moving average price is $14.56 and its two-hundred day moving average price is $9.68. The company has a market cap of $1.23 billion, a PE ratio of -15.47 and a beta of 1.34. Silence Therapeutics has a twelve month low of $4.19 and a twelve month high of $19.86.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SLN shares. HC Wainwright downgraded Silence Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $75.00 to $20.00 in a report on Wednesday, October 21st. Chardan Capital downgraded shares of Silence Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 21st. Jefferies Financial Group downgraded shares of Silence Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 target price on the stock. in a report on Monday, October 19th. William Blair lowered shares of Silence Therapeutics from an “outperform” rating to a “hold” rating in a research report on Monday, October 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $24.00.

Silence Therapeutics Company Profile

Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.